The present study is the first to demonstrate that the cGAS‐STING pathway induces PTCL progression and that first‐line chemotherapeutic agents can activate this pathway, potentially leading to relapse or disease progression. The gene discussed is STING1; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.